Repurposing misoprostol for Clostridium difficile colitis as identified by PheWAS
PheWAS 确定米索前列醇重新用于治疗艰难梭菌结肠炎
基本信息
- 批准号:9336367
- 负责人:
- 金额:$ 27.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-01 至 2020-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAntibioticsArachidonic AcidsBacteriaBindingBiological MarkersBody Weight decreasedCessation of lifeClinical DataClinical ResearchClinical TrialsClostridium difficileCodeColitisColonCommunicable DiseasesComputational algorithmDataData SetDevelopmentDiarrheaDinoprostoneDiseaseDoseDrug usageExposure toFDA approvedFecesFeverGastric ulcerGene TargetingGenerationsGeneticGenotypeGoalsHealthHistologicHospitalsICD-9InfectionInflammationLeadLinkLipidsMisoprostolModelingMusNon-Steroidal Anti-Inflammatory AgentsNosocomial InfectionsOral AdministrationPainPatient riskPatientsPharmaceutical PreparationsPharmacologyPhenotypePredispositionPreventionProbioticsProstaglandin E ReceptorProstaglandin-Endoperoxide SynthaseProstaglandinsPublishingQuality of lifeRecurrenceRelapseResearchRiskRunningSepsisSeveritiesSeverity of illnessSynthetic ProstaglandinsTissuesToxic MegacolonToxinUlcerVariantanalogbasecohortcost effectiveeicosanoid metabolismepidemiologic dataexperimental studyfecal transplantationgastrointestinalgut microbiomelipid mediatormetabolomemouse modelnovelphenomepre-clinicalpreclinical studypreventreceptorsuccess
项目摘要
PROJECT SUMMARY:
Clostridium difficile infection (CDI) is a leading nosocomial infection and the primary identifiable cause of
antibiotic-associated diarrhea. It can lead to multiple CDI recurrences, sepsis, toxic megacolon, and death.
Recurrent CDI complicates 20% of primary episodes of disease and is associated with an increased risk of
death and a poor quality of life. While probiotics or fecal transplantation have met with some success in
breaking the cycle of recurrent CDI, there remains a need for simple, safe, and cost-effective solutions to this
problem.
Prostaglandins (PGs) are lipid molecules involved in many aspects of health and disease. The PGs,
especially the molecule PGE2, are important to gastrointestinal health and medications that block their
synthesis, known as nonsteroidal anti-inflammatory drugs (NSAIDs), can cause gastrointestinal problems such
as stomach ulcers. In fact, misoprostol, a PGE analogue, is FDA approved to prevent ulcers in patients taking
NSAIDs. We recently applied a published and publicly available computational algorithm to perform a
phenome-wide association study (PheWAS) based on ICD-9 billing code data in a disease-agnostic cohort of
~40,000 patients to identify potential novel genotype-phenotype associations related to sequence variations in
the genes for the targets of misoprostol (PGE2 receptors). This analysis predicted a possible new indication for
misoprostol to treat (or prevent) C. difficile colitis. Given emerging epidemiological data suggesting that NSAID
use increases the risk for CDI and our new preliminary data in a mouse CDI model showing that exposure to
NSAIDs worsens CDI severity while misoprostol alleviates the disease, we hypothesize that misoprostol can
be repurposed to prevent recurrent C. difficile colitis.
We envision a clinical study using misoprostol to prevent recurrent CDI but there are unanswered
questions that must be addressed before any such clinical trial. These relate particularly to the timing and dose
of the drug. We therefore propose two Aims to (1) define the optimal dose and timing of administration of oral
misoprostol in a mouse model of relapsing CDI and (2) determine the correlates of protection by misoprostol in
a mouse model of relapsing CDI. These studies will examine the impact of misoprostol on factors known to
govern susceptibility to CDI, including changes to the gut microbiome and metabolome, tissue inflammation,
and the generation of biomarkers of colitis.
These studies are a critical first step in moving toward clinical studies of CDI treatment and/or
prevention that exploit the beneficial effects of PGE2 on colon health. The successful completion of these
studies will have immediate impact on new clinical studies of CDI and may provide evidence for more rationale
use of NSAIDs or prostaglandin analogues in high CDI-risk patients.
项目总结:
艰难梭菌感染(CDI)是一种主要的医院感染,也是引起肺炎的主要原因。
抗生素相关性腹泻。它可能导致多次CDI复发、败血症、中毒性巨结肠和死亡。
复发的CDI会使20%的初始疾病发作复杂化,并与增加
死亡和低劣的生活质量。虽然益生菌或粪便移植在
打破重复的CDI循环,仍然需要简单、安全和经济有效的解决方案来解决这个问题
有问题。
前列腺素(PGs)是一种脂分子,与健康和疾病的许多方面有关。篮球队,
尤其是PGE2分子,对胃肠道健康和阻断其活性的药物都很重要。
合成,被称为非类固醇抗炎药(NSAIDs),可导致胃肠道问题,如
作为胃溃疡。事实上,米索前列醇是一种前列腺素E类似物,FDA批准用于预防服用
非甾体抗炎药。我们最近应用了一种公开发布的计算算法来执行
基于ICD-9计费代码数据的表型组范围关联研究(Phewas)
约40,000名患者,以确定与基因序列变异相关的潜在新的基因-表型关联
米索前列醇靶标基因(PGE2受体)。这一分析预测了一个可能的新迹象
米索前列醇用于治疗(或预防)艰难梭菌结肠炎。鉴于新出现的流行病学数据表明非甾体抗炎药
使用CDI增加了CDI的风险,我们在小鼠CDI模型中的新初步数据显示,暴露于
非甾体抗炎药加重CDI严重程度而米索前列醇减轻疾病,我们假设米索前列醇可以
用于预防艰难梭状芽胞杆菌结肠炎复发。
我们设想了一项使用米索前列醇预防CDI复发的临床研究,但没有得到回应
在任何这样的临床试验之前必须解决的问题。这些特别与时间和剂量有关。
药物的作用。因此,我们提出了两个目标:(1)确定口服的最佳剂量和时间
米索前列醇在复发性CDI小鼠模型中的作用和(2)确定米索前列醇对CDI的保护作用的相关性
复发性CDI小鼠模型的建立。这些研究将检查米索前列醇对已知的
控制对CDI的敏感性,包括肠道微生物组和代谢组的变化,组织炎症,
结肠炎生物标志物的产生。
这些研究是迈向CDI治疗和/或临床研究的关键的第一步
利用PGE2对结肠健康的有益影响进行预防。这些项目的顺利完成
研究将对CDI的新临床研究产生直接影响,并可能为更多的理论基础提供证据
非甾体抗炎药或前列腺素类似物在CDI高危患者中的应用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David M Aronoff其他文献
Infections caused by emClostridium perfringens/em and emPaeniclostridium sordellii/em after unsafe abortion
不安全流产后由产气荚膜梭菌和索氏梭菌引起的感染
- DOI:
10.1016/s1473-3099(22)00590-4 - 发表时间:
2023-02-01 - 期刊:
- 影响因子:31.000
- 作者:
David M Aronoff;Jeanne M Marrazzo - 通讯作者:
Jeanne M Marrazzo
David M Aronoff的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David M Aronoff', 18)}}的其他基金
Bacterial CRISPR interference to define macrophage responses to group B Streptococcus proteins
细菌 CRISPR 干扰定义巨噬细胞对 B 族链球菌蛋白的反应
- 批准号:
10724607 - 财政年份:2023
- 资助金额:
$ 27.65万 - 项目类别:
The Role of macrophages in chorioamnionitis and group B streptococcal infections
巨噬细胞在绒毛膜羊膜炎和 B 族链球菌感染中的作用
- 批准号:
10576123 - 财政年份:2017
- 资助金额:
$ 27.65万 - 项目类别:
Determining the contribution of zinc deficiency to perinatal Group B Streptococcus infections
确定锌缺乏对围产期 B 族链球菌感染的影响
- 批准号:
10163224 - 财政年份:2017
- 资助金额:
$ 27.65万 - 项目类别:
The Role of macrophages in chorioamnionitis and group B streptococcal infections
巨噬细胞在绒毛膜羊膜炎和 B 族链球菌感染中的作用
- 批准号:
9978691 - 财政年份:2017
- 资助金额:
$ 27.65万 - 项目类别:
The Role of macrophages in chorioamnionitis and group B streptococcal infections
巨噬细胞在绒毛膜羊膜炎和 B 族链球菌感染中的作用
- 批准号:
10211123 - 财政年份:2017
- 资助金额:
$ 27.65万 - 项目类别:
Determining the contribution of zinc deficiency to perinatal Group B Streptococcus infections
确定锌缺乏对围产期 B 族链球菌感染的影响
- 批准号:
9381886 - 财政年份:2017
- 资助金额:
$ 27.65万 - 项目类别:
The Role of macrophages in chorioamnionitis and group B streptococcal infections
巨噬细胞在绒毛膜羊膜炎和 B 族链球菌感染中的作用
- 批准号:
9403144 - 财政年份:2017
- 资助金额:
$ 27.65万 - 项目类别:
Prostaglandins as protective mediators in Clostridium difficile infection
前列腺素作为艰难梭菌感染的保护介质
- 批准号:
9316517 - 财政年份:2016
- 资助金额:
$ 27.65万 - 项目类别:
Mechanisms of group B streptococcal interactions with extraplacental membranes
B 族链球菌与胎盘外膜相互作用的机制
- 批准号:
8507835 - 财政年份:2012
- 资助金额:
$ 27.65万 - 项目类别:
Epidemiology and Genomics of Clostridium difficile
艰难梭菌的流行病学和基因组学
- 批准号:
8026742 - 财政年份:2010
- 资助金额:
$ 27.65万 - 项目类别:
相似海外基金
Can antibiotics disrupt biogeochemical nitrogen cycling in the coastal ocean?
抗生素会破坏沿海海洋的生物地球化学氮循环吗?
- 批准号:
2902098 - 财政年份:2024
- 资助金额:
$ 27.65万 - 项目类别:
Studentship
The role of RNA repair in bacterial responses to translation-inhibiting antibiotics
RNA修复在细菌对翻译抑制抗生素的反应中的作用
- 批准号:
BB/Y004035/1 - 财政年份:2024
- 资助金额:
$ 27.65万 - 项目类别:
Research Grant
Metallo-Peptides: Arming Cyclic Peptide Antibiotics with New Weapons to Combat Antimicrobial Resistance
金属肽:用新武器武装环肽抗生素以对抗抗菌素耐药性
- 批准号:
EP/Z533026/1 - 财政年份:2024
- 资助金额:
$ 27.65万 - 项目类别:
Research Grant
Towards the sustainable discovery and development of new antibiotics
迈向新抗生素的可持续发现和开发
- 批准号:
FT230100468 - 财政年份:2024
- 资助金额:
$ 27.65万 - 项目类别:
ARC Future Fellowships
DYNBIOTICS - Understanding the dynamics of antibiotics transport in individual bacteria
DYNBIOTICS - 了解抗生素在单个细菌中转运的动态
- 批准号:
EP/Y023528/1 - 财政年份:2024
- 资助金额:
$ 27.65万 - 项目类别:
Research Grant
Engineering Streptomyces bacteria for the sustainable manufacture of antibiotics
工程化链霉菌用于抗生素的可持续生产
- 批准号:
BB/Y007611/1 - 财政年份:2024
- 资助金额:
$ 27.65万 - 项目类别:
Research Grant
The disulfide bond as a chemical tool in cyclic peptide antibiotics: engineering disulfide polymyxins and murepavadin
二硫键作为环肽抗生素的化学工具:工程化二硫多粘菌素和 murepavadin
- 批准号:
MR/Y033809/1 - 财政年份:2024
- 资助金额:
$ 27.65万 - 项目类别:
Research Grant
Role of phenotypic heterogeneity in mycobacterial persistence to antibiotics: Prospects for more effective treatment regimens
表型异质性在分枝杆菌对抗生素持久性中的作用:更有效治疗方案的前景
- 批准号:
494853 - 财政年份:2023
- 资助金额:
$ 27.65万 - 项目类别:
Operating Grants
Imbalance between cell biomass production and envelope biosynthesis underpins the bactericidal activity of cell wall -targeting antibiotics
细胞生物量产生和包膜生物合成之间的不平衡是细胞壁靶向抗生素杀菌活性的基础
- 批准号:
2884862 - 财政年份:2023
- 资助金额:
$ 27.65万 - 项目类别:
Studentship
Narrow spectrum antibiotics for the prevention and treatment of soft-rot plant disease
防治植物软腐病的窄谱抗生素
- 批准号:
2904356 - 财政年份:2023
- 资助金额:
$ 27.65万 - 项目类别:
Studentship